The transformation of normal hematopoietic cells to leukemic cells requires cells to acquire two intrinsic changes. These are the acquisition by some method of autocrine growth stimulation and a perturbation of differentiation commitment leading to abnormal levels of self-generation. Hematopoietic regulator action can be involved to produce or facilitate both these changes but the same regulators can also suppress some leukemic populations by enforced differentiation commitment.
Introduction
It is a particular pleasure for me to present this Memorial Lecture. Charlotte Friend was a warm, gentle human and a loyal colleague and friend. Jacob Furth and I in Boston were to know her well through joint studies in 1957 and 1958 involving the first use outside her laboratory of the virus that came to carry her name. She later worked in my laboratory in Melbourne while on a Travelling Fellowship from the Sloan-Kettering Memorial Hosptial. Recognition of her accomplishments was slow and grudging. In the mid-1950s it did not sit well with the research establishment to be a woman scientist, to be untrained as a pathologist yet to discover a powerful leukemia-inducing virus and to encounter a then unfamiliar situation of viral-driven, unrestrained, hematopoietic proliferation where the affected cells only much later transform to bona fide transplantable leukemic cells. As we shall see, this problem remains with us today, as a vexing question in a number of leukemias. She was also one of the first workers to document that undifferentiated leukemic cells could be induced to differentiate unequivocally, in her case to maturing erythroid cells, by exposure of leukemic cell lines to chemical agents such as DMSO. This is now a familar biological phenomenon with at least certain leukemias, but not generally so, again leaving us with a continuing problem to be resolved. To break new ground in two major areas of cancer biology arouses skepticism and criticism but fortunately, in Charlotte's case, scientific fairness won out and she was to be acknowledged for her accomplishments by many honors, including Presidency of the American Association for Cancer Research.
Both of the phenomena encountered by her have become central issues in our own work and will be discussed in the account to follow. 
Hematopoiesis
This account will be restricted mainly to myeloid leukemianeoplasms that overtly involve the granulocyte-macrophage subset of hematopoietic cells. To set the scene for the discussion to follow, it is necessary to summarize briefly our current understanding of the molecular control of granulocytemacrophage populations. Committed granulocyte-macrophage progenitor cells are generated from multipotential stem cells and expend themselves in the production of maturing granulocytes and macrophages. As shown in Figure 1 , a large number of hematopoietic regulators have been identified as having some ability to regulate this process. For the generation of progenitor cells from stem cells, stem cell factor (SCF) and Flk-ligand (FL) stand out as key regulators. Stem cell proliferation requires simultaneous stimulation by two or more regulators and IL-3, IL-7, G-CSF, GM-CSF, IL-6 and IL-11 have all been shown to be active partners for SCF or FL in their stimulation of stem cell proliferation.
Control of the production by progenitor cells of mature granulocytes and macrophages is mediated by the four colonystimulating factors, G-CSF, GM-CSF, M-CSF and Multi-CSF (IL-3) but IL-6 and SCF are also active on granulocyte formation. 1 Stimulation is essential for all cell division and the cell cycle times of responding cells are determined by the regulator con-
Figure 1
The hematopoietic regulators controlling the formation of progenitor cells by stem cells and the formation of maturing granulocytes and macrophages by committed progenitor cells. Regulators shown in bold print have been shown to be quantitatively important by gene inactivation studies.
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centration. While single regulators can stimulate progenitor cell proliferative activity, combinations often exhibit strong synergy. For both stem and progenitor cells, co-action of regulators is made possible by the simultaneous display on individual cells of receptors for more than one regulator.
All hematopoietic growth factors are polyfunctional. In addition to stimulating cell division, these regulators can initiate differentiation commitment and maturation, can regulate many aspects of membrane transport and thus cell viability and can enhance the functional activity of the mature cells. These multiple functions are made possible by functional specialization in the receptor chains -distinct regions of the receptor chain initiating special mitotic, differentiative or maturation signals. 
Leukemogenesis
Studies using murine models have indicated that two major types of abnormality must be acquired by a hematopoietic cell if it is to transform from a normal state to a fully-developed leukemic cell. 2 These are: (1) acquisition by some mechanism of an abilty to proliferate independently of extrinsic growth factors, so-called autocrine growth stimulation; and (2) acquisition of an anomaly in differentiation commitment, allowing an abnormally high proportion of the progeny generated to be parental-like, so-called self-generation. The sequence in which these changes is acquired does not seem to be critical as there are models in which leukemic cells emerge with either sequence.
A third class of acquired abnormality of relevance in leukemia are changes leading to extended lifespans of the cells and avoidance of apoptosis. The prototype example involves the bcl-2 gene which is characteristically overexpressed in follicular lymphoma cells, and whose product is anti-apoptotic in action. 3, 4 Anomalies of this type appear not to be directly responsible for leukemic transformation but allow survival of cells with one or other of the above abnormalities, enabling second abnormalities to occur, thereby completing the required set of changes.
Autocrine growth stimulation
The simplest models documenting the role of autocrine growth stimulation in leukemogenesis involve the use of the non-leukemic, but immortalized, murine cell line FDC-P1 -a growth factor-dependent myeloid cell line requiring either GM-CSF or IL-3 for survival and proliferation, the cells already possessing an abnormally high capacity for self-generation (greater than 80%). Insertion and independent expression of cDNA encoding either GM-CSF or IL-3 in these cells promptly transforms them to leukemic cells. [5] [6] [7] In most instances, acquisition by the cells of the ability to produce their own growth factor leads to their autonomous growth in vitro. There is an almost universal rule in leukemic biology that autonomous growth in vitro equates with an ability to generate transplanted leukemias when the cells are tested in syngeneic recipients. However, there are exceptions to this rule. Some FDC-P1 cells transformed by insertion of IL-3 cDNA are leukemogenic but continue to exhibit absolute dependency in vitro on stimulation by extrinsic IL-3 for survival and proliferation. Conversely, some cell lines derived from fetal liver and transformed to autonomy by infection with v-mpl, the activated receptor for thrombopoietin, do not behave as leukemic cells These experiments raise a series of problems regarding the leukemic cells in human AML and CML. Cells from both types of patient are clonogenic in agar cultures but in the large majority of instances, the in vitro growth of the leukemic cells is not autonomous and remains wholly dependent on stimulation by added growth factors. 2 From the above rule about the equivalence of autonomy and leukemogenicity, this would suggest that the cells involved were not truly leukemogenic as defined by a transplantation test.
Studies on the ability of AML cells to produce relevant growth factors have indicated that they often do transcribe mRNA for potentially relevant growth factors, a transcription that is highly inducible by IL-1. 8, 9 Bioassays for secreted growth factors have been more ambiguous although the results again suggest that the production and secretion of active growth factors can occur.
A number of possibilities have been raised by these anomalous findings. First, the cells may be like FDC-P1 cells transformed by IL-3 cDNA where autocrine growth factor production certainly conferred leukemogenicity but the cells remain factor-dependent in vitro for some reason. Second, the clonogenic assays, whether for conventional granulocyte-macrophage colony-forming cells or for blast colonies, may not in fact detect the true leukemogenic stem cell. In this context, tests using AML cells in SCID mice suggested that only one in 250 000 cells is truly clonogenic, as defined by an ability to generate progressive disease in the recipient animals. 10 This is in sharp contrast to the high frequency of colony-forming cells in CML (100% for purified blast cells) and the highly variable, but sometimes up to nearly 100%, clonogenicity of AML cells. The in vitro growth pattern of these clonogenic cells also raises questions. CML cells generate normal maturing granulocyte-macrophage colonies of unremarkable size.
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This is consistent enough with the obvious production of maturing cells by the CML clone in vivo. However, AML cells typically exhibit feeble proliferative activity in vitro to form only small clusters 12 which is at odds with their undoubted proliferative activity in vivo and maturation in these in vitro clusters is either non-existent or aberrant. Because the required growth factors used in vitro, such as the CSFs, also have a capacity to truncate proliferation by enforced differentiation commitment, 1 one possibility is that extrinsic growth factor stimulation in vitro, the very maneuver required to stimulate their proliferation, in fact simultaneously suppresses the extended proliferative capacity of these cells by enforced differentiation commitment. Alternatively, it has been shown that if autonomous leukemic cells are exposed to agents initiating differentiation commitment, the cells then become dependent on stimulation by extrinsic growth factors for survival and proliferation in vitro. 13, 14 These various possibilities remain to be resolved.
In model studies using FDC-P1 cells, it is surprising how often acquisition of autonomy has been based on acquired autocrine growth factor production. When FDC-P1 cells are engrafted into irradiated recipients, the injected cells after a variable, but often long, delay do transform to leukemic cells 15, 16 and analysis showed most often that this was based on insertion of an IAP particle upstream of either the GM-CSF or IL-3 gene leading to autocrine production of one or other growth factor. 17 A similar outcome was observed when FDC-P1 cells were injected into transgenic GM-CSF mice having excessive circulating levels of GM-CSF. 18 Despite the constant availability of sufficient extrinsic growth factor to ensure the proliferation of the FDC-P1 cells, again tranformation virtually was always associated with an acquired ability to produce autocrine GM-CSF or IL-3. Furthermore, when the Moloney virus was used to transform FDC-P1 cells in vitro, again transformation involved autocrine growth factor production, presumably by insertional activation, since this virus lacks an oncogene. 19 Even transformation of FDC-P1 cells by the insertion of excess numbers of M-CSF receptors involved the production by the altered cells of M-CSF. 20 A similar maneuver of exposing Ba/F3 cells expressing c-mpl to a chemical carcinogen led to an autonomous mutant producing thrombopoietin and the method by which one group was able to purify and clone this growth factor. 21 This recurrent pattern might give the impression that leukemic transformation always involves autocrine growth factor production but this is clearly not the case and may reflect a curious predisposition of FDC-P1 or Ba/F3 cells for transformation by this method.
From what is now known about the mitotic signaling pathway, cells should equally be able to achieve autocrine growth stimulation by two other types of mechanism: (1) production of constitutively activated receptors where mutations in the receptor chain allow spontaneous dimer formation or activate the chain by other mechanisms; or (2) dysregulated production of an activated, or surrogate molecule in the mitotic signaling cascade. Examples of both are well documented. Mutated dimer-forming receptors for erythropoietin induce autonomous proliferation when transfected into cells, 22 as do mpl receptors with comparable activating mutations. 23 Similarly, transformation of cells can be achieved using polyoma middle-T antigen, 24 v-abl 25 or bcr-abl, 26 acting as surrogate signaling intermediates. Of particular interest in the context of the present discussion is the fact that the focus-forming viral component of the Friend virus complex is able to induce the characteristic erythroid proliferation because the viral-encoded gp55 moiety can interact with and activate the erythropoietin receptor to achieve ligand-independent signaling, thus relieving the cells of their dependency on extrinsic growth factor stimulation. 27 It remains unclear how commonly these alternative methods are operating in human AML or CML. In the case of CML, the bcr-abl constitutively activated kinase 26 seems likely to provide the autocrine proliferative signal component necessary in leukemogenesis. However, no comparable anomalous proliferative signaling product has been noted in the various subtypes of AML and analyses of receptors for a number of growth factors of likely relevance has so far not detected activating mutations.
Altered self-renewal
When immortalized cells such as FDC-P1 are used, transformation was readily accomplished by inducing changes resulting in autocrine growth. This contrasted sharply with the outcome of inserting growth factor cDNA into normal hematopoietic cells. When this was done with GM-CSF, 28 G-CSF, 29 IL-3 30 and Epo, 31 sustained, presumptively self-stimulated, growth was obtained and animals repopulated by such cells developed a vast excess of cells exhibiting receptors for the growth factor involved. The invasion of non-hematopoietic organs like lung and liver was sometimes massive and gave the superficial histological appearance of leukemia. However, the cells from such animals did not behave as leukemic cells on transplantation. While such experiments fall into the controversial grey area between hyperplasia and leukemia, it was obvious that genuine leukemia, as defined by the gold standard of transplantability, was not being achieved.
There is no current molecular explanation of the nature of immortalization as exhibited by cells such as FDC-P1. Biologically, however, it is obvious that they have a self-renewal capacity far in excess of the 50% level assumed to be the situation in normal self-maintaining populations like bone marrow stem cells. There could indeed be multiple relevant abnormalities pre-existing in FDC-P1 cells but the simplest assumption is that a single critical abnormality can lead to the formation, after cell division, of an excess of parental-type progeny.
This simplified assumption has been validated in studies in which two genes were introduced simultaneously into normal hematopoietic cells -the IL-3 gene and Hox 2.4 gene. The Hox 2.4 product has the ability to enhance self-renewal in a subset of primitive hematopoietic cells. 32 Combined expression of both genes led to the immediate transformation of affected cells to readily transplantable myeloid leukemic cells, resembling WEHI 3B leukemic cells, 33 the cell line originally demonstrated to be overexpressing Hox 2.4 and IL-3.
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While Hox 2.4 is not recognized as a likely candidate for involvement in human leukemias, there are several candidates that may have an influence on commitment, differentiation induction or self-renewal. Prominent among these is the aberrant PML-RAR fusion product characteristic of APL with its maturation arrest at the promyelocyte stage. 36 Indeed, construction of transgenic PML-RAR mice has been noted to lead to the development of a disease state resembling APL, although the evidence is not yet overwhelming that the cells are unequivocally leukemic. 37 In acute T lymphocyte leukemias, aberrant expression of SCL is a common occurrence 38 and, when SCL is overexpressed, it has the capacity to prevent differentiation commitment in the M1 leukemic cell line normally able to be induced by LIF or OSM. 39 When expressed in T lymphocyte cell lines, SCL induced more rapid transformation to lymphoid leukemia 40 and transgenic SCL mice developed an increased incidence of lymphoid leukemia. 41 There is abundant evidence that cooperation between pairs of oncogenes promotes leukemia development 42 and the temptation is therefore strong to assume that one oncogene is providing autocrine stimulation while the second interferes with self-renewal. An example that potentially fits this view would be the cooperation between myc and ras, myc being an essential signaling molecule for cell proliferation while ras, at least in C. elegans and yeast, affects differentiation.
Regulator suppression of leukemia
As noted earlier, Charlotte Friend was able to induce terminal erythroid differentiation in erythroleukemic cells using DMSO 43 and subsequently a wide range of chemical agents was observed to have a similar action. Extension of this work to murine and human myeloid leukemic cell lines identified a similar series of chemical agents able to induce granulocytic or, more often, monocyte-macrophage differentiation. 44 While these systems are highly artificial they did raise two points of fundamental importance in leukemia. First, the data indicated that leukemic cells were not irreversibly frozen in an undifferentiated state -a fact clearly evident in CML and to a lesser degree in AML. Second, the data raise the possi-S11 bility of suppressing a leukemic population by enforced differentiation of the cells to cells that, if not entirely normal, are none the less post-mitotic.
Few of the many active chemical agents could be regarded as being likely to represent normal physiological regulatory molecules. However, in this context, the recognition of the polyfunctionality of hematopoietic regulators 1 became of interest, since one of their actions is differentiation commitment and maturation induction.
On this basis, tests of GM-CSF and G-CSF [45] [46] [47] clearly showed the ability of these agents, when acting on suitable leukemic cell lines, to suppress clonogenic self-renewal with or without an accompanying maturation. With the subsequent discovery of the LIF, IL-6, OSM group of regulators, signaling through a common gp130 receptor chain, regulators became available with an exceedingly powerful ability to, at times, totally suppress the commonly used M1 murine leukemic cell line, with macrophage maturation as an alternative fate of some of the cells. 14, 48 Indeed, experiments in this laboratory with M1 or WEHI 3B leukemic cell lines expressing a wide range of inserted receptors such as those for human GM-CSF or murine M-CSF, G-CSF, TPO or leptin have shown that the relevant ligand can then actively suppress the leukemic cells. This indicates that this type of cellular response is quite promiscuous, at least in terms of the initial signaling events in the cascade activated when ligand binds to its receptor. Analysis of M1 and WEHI-3B cells with inserted mutated receptor chains has identified specific regions of the receptor necessary to initiate this differentiation commitment -regions that are separate from the Box 1-Box 2 juxtamembrane regions necessary for mitotic signaling. 49 These studies have raised the intriguing possibility that regulators might be useful clinical agents to suppress a myeloid leukemic population, despite the fact that receptor signaling would also potentially stimulate the proliferation of such cells. Clinical experience with the use of GM-CSF or G-CSF in myeloid leukemic patients has documented their cycle-activating action on leukemic cells 50, 51 but has yet to document an induction of maturation in any way approaching that achievable by retinoic acid in the treatment of APL patients.
There are several obvious problems in this approach. Analysis of AML populations has shown, for example, that many populations express G-CSF receptors but autoradiographic studies have shown that often not all of the leukemic blast cells in the population express such receptors and could not therefore be expected to be responsive to G-CSF inhibition. 52 APL populations were exceptional in this regard in uniformly expressing high numbers of G-CSF receptors. 53 More seriously, most leukemic populations and cell lines are quite unresponsive to cytokine-induced differentiation.
This latter problem has prompted studies in this laboratory to establish the basis for the appearance of differentiationresistant mutants in the normally highly responsive M1 leukemic cell line, using IL-6 as a powerful inducing agent. Initial studies used carcinogens to generate mutated-resistant cell lines and these studies coupled with fusion studies of such cells to parental M1 cells documented that the most common resistant mutants were, in fact, recessive mutants based on failure to express the gp130 receptor chain. Insertion of gp130 receptor chains into such cells, or fusion of the cells with the parental strain cells, reactivated responsiveness to suppression by IL-6.
In an attempt to identify genes conferring dominant resistance to IL-6, a different strategy was adopted. In this, M1 leukemic cells were transfected with a retroviral library containing cDNA from the immortalized cell lines FDC-P1. The genes responsibile for the emergence of any resistant clones observed could then be identified in making use of the retroviral tag on the inserted cDNA. The first IL-6-resistant clone analyzed identified the inserted cDNA as encoding a novel protein (SOCS-1) with an SH2 domain and a C-terminal region homologous with the pseudosubstrate regions of JAK kinases. 54 Transfection of SOCS-1 into M1 cells conferred on them resistance to differentiation induction by IL-6, LIF or OSM but did not render the cells unresponsive to differentiation induction by dexamethasone. A data-base search has identified 12 other members of this gene family, some of which have now been isolated and found to act in a comparable manner to SOCS-1. SOCS-1 interferes with phosphorylation and activation of gp130 and STAT3 and appears therefore to have the capacity to modulate and block certain of the signaling cascades normally able to induce differentiation commitment. 54, 55 Transcription of the SOCS genes can be induced in leukemic and normal cells by cytokine signaling but the induction patterns of the different members of this family differ, raising the possibility of quite subtle modulation of signaling pathways in response to cytokine stimulation.
These studies have identified a new class of cytoplasmic modulators of signaling. While it is too early to know whether any of the family are responsible for the unresponsiveness of human myeloid leukemic populations or for the differentiation anomalies in the myelodysplasias, it is reasonable to expect that they may well play a role in these disease states.
Concluding comments
While the molecular control of hematopoiesis is becoming well understood, it is proving difficult to relate this information to the clearly emerging gene abnormalities in particular types of human leukemia. Connections must exist and simplified murine models document the general nature of such connections. Nevertheless, comparable models cannot yet be constructed for any one type of human leukemia and until this is achieved, it is not likely that advances will be possible in the management of leukemia that would represent a significant improvement over the present use of highly toxic and unselective chemotherapy.
Without being in a position to recognize the full implications of her early observations, Charlotte Friend pursued her studies with care and enthusiasm. Her work was the forerunner of much of the current work on the nature and control of leukemia and she deserves our respect and acknowledgement for her pioneering work.
